Study summary
Amivantamab plus lazertinib helped people live longer than osimertinib
60%alive at 3 years, vs 51% with osimertinib
What was tested
Amivantamab, an antibody that blocks both EGFR and MET, plus lazertinib, an EGFR pill, against osimertinib alone as first treatment for advanced EGFR-mutated lung cancer.
What they found
- 3-year overall survival was 60% vs 51%.
- Severe side effects were more common (80% vs 52%), especially skin problems, blood clots and infusion reactions.
What it means
A second first-line option that adds survival, at the cost of more side effects and regular infusions.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.